Evidence map›Paper›PMID 34253060›Full record

ArticlemBio2021

Silvie Van den Hoecke, Marlies Ballegeer, Bram Vrancken, Lei Deng, Emma R Job, Kenny Roose, Bert Schepens, Lien Van Hoecke, Philippe Lemey, Xavier Saelens

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Frontiers in immunology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Silvie Van den Hoecke *VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Marlies Ballegeer *VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Bram VranckenKU Leuven-University of Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium.
Lei DengVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Emma R JobVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Kenny RooseVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Bert SchepensVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Lien Van HoeckeDepartment of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Philippe LemeyKU Leuven-University of Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium.
Xavier SaelensVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Ghent University · BERega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ectodomain of matrix protein 2 (M2e) of influenza A viruses is a universal influenza A vaccine candidate. Here, we report potential evasion strategies of influenza A viruses under

Indexed as

MutationAnimalsAntibodies, ViralHigh-Throughput Nucleotide SequencingImmune EvasionImmunoglobulin GInfluenza A virusMiceMice, Inbred BALB CMice, SCIDViral Matrix ProteinsAntibodies, ViralImmunoglobulin GM1 protein, Influenza A virusViral Matrix Proteinsbroadly protectivedeep sequencingescapeimmunotherapyinfluenzamonoclonal antibodies

Identifiers

PMID34253060
PMCPMC8406285
OpenAlexW3182642892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.